Ignite Creation Date:
2024-05-05 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00111813
Status:
COMPLETED
Last Update Posted:
2015-05-21
First Post:
2005-05-25
Brief Title:
Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma MK-0683-015 EXT 1 AM1
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
Phase I Clinical Trial of Vorinostat MK-0683 in Combination With Bortezomib in Patients With Advanced Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of this study are
To determine the maximum tolerated dose MTD for the combination of oral vorinostat and bortezomib in participants with advanced multiple myeloma
To assess the safety and tolerability of this regimen and to document the participants clinical status by anti-tumor activity for this combination as determined per standard of care
To determine the maximum tolerated dose MTD for the combination of oral vorinostat and bortezomib in participants with advanced multiple myeloma
To assess the safety and tolerability of this regimen and to document the participants clinical status by anti-tumor activity for this combination as determined per standard of care
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_018 | None | None | None |